H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study

作者：Walker Woolf T; de Whalley Philip; Andrews Nick; Oeser Clarissa; Casey Michelle; Michaelis Louise; Hoschler Katja; Harrill Caroline; Moulsdale Phoebe; Thompson Ben; Jones Claire; Chalk Jem; Kerridge Simon; John Tessa M; Okike Ifeanyichukwu; Ladhani Shamez; Tomlinson Richard; Heath Paul T; Miller Elizabeth; Faust Saul N^*; Snape Matthew D; Finn Adam; Pollard Andrew J

来源：Clinical Infectious Diseases, 2012, 54(5): 661-669.

DOI：10.1093/cid/cir905

Background. We investigated antibody persistence in children 1 year after 2 doses of either an AS03B-adjuvanted split-virion or nonadjuvanted whole-virionmonovalent pandemic influenza vaccine and assessed the immunogenicity and reactogenicity of a subsequent dose of trivalent influenza vaccine (TIV). %26lt;br%26gt;Methods. Children previously immunized at age 6 months to 12 years in the original study were invited to participate. After a blood sample was obtained to assess persistence of antibody against swine influenza A/H1N1(2009) pandemic influenza, children received 1 dose of 2010/2011 TIV, reactogenicity data were collected for 7 days, and another blood sample was obtained 21 days after vaccination. %26lt;br%26gt;Results. Of 323 children recruited, 302 received TIV. Antibody persistence (defined as microneutralization [MN] titer %26gt;= 1:40) 1 year after initial vaccination was significantly higher in the AS03(B)-adjuvanted compared with the whole-virion vaccine group, 100% (95% confidence interval [CI], 94.1%-100%) vs 32.4% (95% CI, 21.5%-44.8%) in children immunized %26lt; 3 years old and 96.9% (95% CI, 91.3%-99.4%) vs 65.9% (95% CI, 55.3%-75.5%) in those 3-12 years old at immunization, respectively (P %26lt; .001 for both groups). All children receiving TIV had post-vaccination MN titers %26gt;= 1:40. Although TIV was well tolerated in all groups, reactogenicity in children %26lt; 5 years old was slightly greater in those who originally received AS03(B)-adjuvanted vaccine. %26lt;br%26gt;Conclusions. This study provides serological evidence that 2 doses of AS03(B)-adjuvanted pandemic influenza vaccine may be sufficient to maintain protection across 2 influenza seasons. Administration of TIV to children who previously received 2 doses of either pandemic influenza vaccine is safe and is immunogenic for the H1N1 strain.

• 出版日期2012-3-1